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1. Introduction
The non‐segmented negative‐sense (NNS) RNA viruses encompass a wide range of signifi‐
cant human, animal, and plant pathogens including several National Institute of Allergy
and Infectious Diseases (NIAID) Category A and C biodefense pathogens. The NNS RNA
viruses are classified into four families: the Rhabdoviridae, as exemplified by rabies virus and
vesicular stomatitis virus (VSV); the Paramyxoviridae, as exemplified by human respiratory
syncytial virus (RSV), human metapneumovirus (hMPV), human parainfluenza virus type 3
(PIV3), measles virus, mump virus, Newcastle disease virus (NDV), Nipah virus, and Hen‐
dra virus; the Filoviridae, as exemplified by Ebola and Marburg viruses; and the Bornaviridae,
as exemplified by Borna disease virus. For many of these viruses, there are no effective vac‐
cines or anti-viral drugs. RSV, hMPV, and PIV3 account for more than 70% of acute viral
respiratory diseases, especially in infants, children, and the elderly [1, 2]. hPIV 1-3 have been
recognized as the causative agents of croup since the late 1950’s [3]. In addition, measles re‐
mains a major killer of children worldwide, despite successful vaccination programs in de‐
veloped countries [4]. The most virulent strains of NDV, the viscerotropic velogenic strains
(often called “exotic” NDV), are classified as High Consequence Livestock Pathogens by US‐
DA due to their potential as agents of agricultural bioterrorism [5].
Messenger RNA modification is the essential issue in NNS RNA virus gene expression and
replication. During viral RNA synthesis, NNS RNA viruses produce capped, methylated, and
polyadenylated mRNAs [6-8]. Cap formation is essential for mRNA stability, efficient transla‐
tion, and gene expression [9-11]. It is now firmly established that mRNA capping and methyla‐
tion in NNS RNA viruses evolves in a mechanism distinct to their hosts [12-19]. Thus, mRNA
cap formation is an attractive antiviral target for NNS RNA viruses. For decades, VSV has been
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used as a model to understand the replication and gene expression of NNS RNA viruses. Most
of our understanding of mRNA modifications of NNS RNA viruses comes from studies of
VSV, a prototype of the Rhabdoviridae family. Using VSV as a model, we will discuss (i) the un‐
usual mechanism of mRNA capping and cap methylation; (ii) the impact of viral mRNA cap
methylation in viral life cycle and viral pathogenesis; and (iii) the applications of viral mRNA
cap methylation in the development of novel vaccines and broadly-active anti-viral agents.
2. Overview diagram of VSV mRNA synthesis and modifications
2.1. The structure of VSV virions
VSV virions are bullet-shaped particles 170 nm in length and 80 nm in diameter (Fig.1). Among
NNS RNA viruses, VSV has the simplest RNA genome consisting of 11,161 nucleotides (nt) or‐
ganized into five VSV genes encoding nucleocapsid (N), phospho- (P), matrix (M), glyco- (G),
and large (L) proteins, and leader and trailer regulatory sequences arranged in the order 3’-
(leader), N, P, M, G, L, (trailer)-5’[20-23]. Like all NNS RNA viruses, the genome is encapsidated
with the N protein to form a nuclease-resistant helical N-RNA complex that is the functional
template for mRNA synthesis as well as genomic RNA replication. The N-RNA complex is tight‐
ly associated with the viral RNA-dependent RNA polymerase (RdRp), which is comprised of
the 241-kDa L protein catalytic subunit and the 29-kDa essential P protein cofactor, and results in
the assembly of a viral ribonucleoprotein (RNP) complex [24, 25]. This structure contains the
minimum virus encoded components of the VSV RNA synthesis machinery [26]. The RNP com‐
plex is further surrounded by the M protein which plays a crucial role in virus assembly, bud‐
ding, and maintenance of the structural integrity of the virus particle [27]. The outer membrane
of virion is the envelope composed of a cellular lipid bilayer. The transmembrane G protein is
anchored in the viral envelope, which is essential for receptor binding and cell entry [28].
2.2. VSV life cycle
The overview picture of VSV life cycle is depicted in Fig.2. Upon attaching to an unknown cell
receptor(s), VSV enters host cells via receptor mediated endocytosis [29]. Following low pH
triggered fusion and uncoating, the RNP complex is delivered into the cytoplasm where RNA
synthesis and viral replication occur [30]. During primary transcription, the input RdRp recog‐
nizes the specific signals in the N-RNA template to transcribe six discrete RNAs: a 47-nucleo‐
tide leader RNA (Le+), which is neither capped nor polyadenylated, and 5 mRNAs that are
capped and methylated at the 5’ end and polyadenylated at the 3’end. These mature mRNAs
are then translated by host ribosomes to yield functional viral proteins which are required for
viral genome replication. During replication, the RdRP initiates at the extreme 3’ end of the ge‐
nome and synthesizes a full-length complementary antigenome, which subsequently serves as
template for synthesis of full-length progeny genomes. These progeny genomes can then be
utilized as templates for secondary transcription, or assembled into infectious particles. Final‐
ly, viral proteins and genomic RNA are assembled into complete virus particles and the virus
exits the cell by budding through the plasma membrane.
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Figure 1. VSV virion structure and genome organization. VSV encodes five structural proteins: nucleocapsid (N),
phospho- (P), matrix (M), glyco- (G), and large (L) proteins. The VSV genome is arranged in the order 3’-(leader), N, P,
M, G, L, (trailer)-5’.
Figure 2. Overview diagram of VSV life cycle. Steps of virus life cycle: attachment, endocytosis, uncoating, genome
replication, mRNA transcription, viral protein translation, viral assembly, and budding are shown.
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2.3. VSV mRNA synthesis and modifications
Our current understanding of VSV mRNA synthesis and modification can be summarized
as follows. In response to a specific promoter element provided by the genomic leader re‐
gion, the polymerase initiates mRNA synthesis at the first gene-start sequence to synthesize
N gene. The nascent mRNA is capped through an unconventional mechanism in which the
GDP: polyribonucleotidyltransferase (PRNTase) of L transfers a monophosphate RNA onto
a GDP acceptor through a covalent protein-RNA intermediate [12, 13, 16]. Following cap ad‐
dition, VSV mRNAs are sequentially methylated at ribose 2’-O position and G-N-7 position,
which is distinct from all known methylation reactions [17, 18]. Unlike traditional cap form‐
ing enzymes, the VSV capping and methylation machinery requires cis-acting signals in the
RNA [12, 18, 31, 32]. When encountering a gene-end sequence, L polyadenylates and termi‐
nates mRNA synthesis by a programmed stuttering of the polymerase on a U7 tract [33, 34].
Termination at the end of the N gene is essential for the polymerase to initiate synthesis at
the start of the next gene, to produce the P mRNA. During transcription, the RdRp complex
transcribes the viral genome into five mRNAs in a sequential and gradient manner, such
that 3′ proximal genes are transcribed more abundantly than 3′ distal genes [21-23]. This
gradient of transcription reflects a poorly understood transcriptional attenuation event that
is localized to the gene junction regions. Using this fashion, VSV produces five capped, me‐
thylated, and polyadenylated mRNAs, N, P, M, G, and L.
3. Large (L) polymerase protein, the multifunctional protein that
modifies viral mRNA
All NNS RNA viruses encode a large (L) polymerase protein, a multifunctional protein rang‐
ing from 220-250kDa in molecular weight. The L protein contains enzymatic activities for nu‐
cleotide polymerization, mRNA cap addition, cap methylation, and polyadenylation. To date,
the structure of L protein, or L protein fragments, has not been determined for any of the NNS
RNA viruses. Amino acid sequence alignment between the L proteins of representative mem‐
bers of each family within NNS RNA viruses has identified six conserved regions numbered I
to VI (CRs I–VI) (Fig.3) [35]. Thus, there is a general assent that the enzymatic activities of L pro‐
tein are located in these conserved regions. For the last four decades, VSV L protein has been
used a model to understand the different activities of NNS RNA virus L proteins because it is
the only member of this order of viruses for which robust transcription can be reconstituted in
vitro [6, 7, 21, 36]. In addition, the VSV L protein can be highly expressed in recombinant expres‐
sion systems, such as E.coli and insect cells. The purified VSV L protein retains all the enzymat‐
ic activities that can modify short virus-specific mRNA in trans [12, 16, 18, 37]. In recent years,
many breakthroughs have been made in the characterization of the function of VSV L protein
and the enzymatic activities have been mapped at the single amino acid level (Fig.3). Within the
primary sequence of L are six conserved regions shared among all NNS RNA virus L proteins.
The RdRP activity has been identified in CR III and this region is also required for polyadenyla‐
tion [38-40]. Consistent with this, a GDN motif is conserved in CR III of all NNS RNA virus L
proteins and is functionally equivalent to the GDD polymerization motif characteristic of posi‐
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tive strand RdRPs. Mutations to the GDN motif of the VSV L protein inactivated polymerase
function [40]. The mRNA capping enzyme maps to CR V [13, 16], and the capping activities of L
differ  from those of  other  viruses  and their  eukaryotic  hosts.  Specifically,  an RNA:GDP
PRNTase activity present within CR V transfers 5′ monophosphate RNA onto a GDP acceptor
through a covalent L-pRNA intermediate [12, 13, 16]. The mRNA cap methyltransferases
(MTase) map to CR VI [14, 17, 19]. Like the unconventional capping enzyme, methylation of the
VSV mRNA cap structure is also unique in that mRNA cap is modified by a dual specificity
MTase activity within CR VI whereby ribose 2′-O methylation precedes and facilitates subse‐
quent guanine-N-7 (G-N-7) methylation [17, 18]. Although functions have not yet to be as‐
signed to the other three conserved regions (CRs I, II, and IV), experiments with Sendai virus
(SeV) have implicated CR I in binding P protein and CR II in binding the RNA template [41, 42].
Figure 3. Conserved regions in L proteins of NNS RNA viruses. Six conserved regions numbered I to VI (CRs I–VI) in L pro‐
tein are shown. Signature motifs for nucleotide polymerization, mRNA cap addition, and cap methylation are shown.
The location of the nucleotide polymerization, capping, and cap methylation activities with‐
in separate regions of L has led to the notion that L protein may be organized as a series of
independent structural domains. Consistent with this idea, a fragment containing CRs V
and VI of the SeV L protein were expressed independently and shown to retain the ability to
methylate short RNAs that corresponded to the 5′ end of SeV mRNA [43]. In addition, re‐
combinant VSV and measles virus can be recovered from infectious cDNA clones by insert‐
ing the coding sequence of green fluorescent protein between CR V and VI in L gene,
suggesting that L protein folds and functions as a series of independent globular domains
[44, 45]. Interestingly, mutations to a variable region between CRs V and VI (residues 1450–
1481) affect mRNA cap MTase activity, feasibly suggesting that mutation to this hinge re‐
gion may affect a conformational change in CR VI [46]. More recently, the molecular archi‐
tecture of VSV L protein has been revealed using negative stain electron microscopy (EM) in
combination with proteolytic digestion and deletion mapping [37]. It was found that VSV L
protein is organized into a ring domain containing the RNA polymerase and an appendage
of three globular domains containing the cap-forming activities. The capping enzyme maps
to a globular domain, which is juxtaposed to the ring, and the cap methyltransferase maps
to a more distal and flexibly connected globule. Interestingly, upon binding to P protein, L
protein undergoes a significant structural rearrangement that may facilitate the coordination
between mRNA synthesis and capping apparatus [37, 47].
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4. An unconventional mRNA capping mechanism in VSV
4.1. Conventional mechanism of mRNA capping in eukaryotic cells
In eukaryotic cells, capping of mRNA is an early posttranscriptional event that is essential
for subsequent processing, nuclear export, stability, and translation of mRNA [11, 48]. Cap
formation is mediated by a series of enzymatic reactions (Fig.4A). First, the 5’ triphosphate
end of the nascent mRNA chain (5’pppN-RNA) is hydrolyzed by an RNA triphosphatase
(RTPase) to yield the diphosphate 5’ ppN-RNA. Second, an RNA guanylyltransferase
(GTase) reacts with GTP to form a covalent enzyme-GMP intermediate and transfers GMP
to 5’ppN-RNA via a 5′-5′ triphosphate linkage to yield 5’ GpppN-RNA. Typically, RNA
GTases contain a signature Kx[D/N]G motif that functions as an active site for the capping
reaction [11, 48, 49]. A lysine residue within Kx[D/N]G motif forms the enzyme-GMP cova‐
lent intermediate, prior to its transfer onto the diphosphate RNA acceptor [11, 48, 50]. This
mRNA capping reaction is conserved among all eukaryotes.
Viruses are highly diverse in capping their mRNA. Many DNA viruses (such as vaccinia vi‐
rus and baculovirus), double stranded RNA viruses (such as reovirus, rotavirus, and blue‐
tongue virus), and single strand positive RNA viruses (such as West Nile virus, Fig.4B)
utilize the conventional eukaryotic capping pathway [51-56]. It has been suggested that
Kx[V/L/I]S motif serve as the GTase active site for reovirus and rotavirus [57]. Other viruses
have evolved different mechanisms for acquiring their cap. For example, influenza virus
and hantavirus furnish their mRNA with this structure by a cap-snatching mechanism, in
which the viral polymerase steals host cell mRNA caps to prime viral mRNA synthesis [58,
59]. The alphaviruses, such as Sindbis, have evolved S-adenosyl-L-methionine(SAM)-de‐
pendent GTase activities that utilize distinct motifs (such as HxH motif) to transfer 7mGp
through a covalent histidine Gp intermediate to form the 7mGpppN cap [60].
4.2. An unconventional mRNA capping mechanism in VSV
In the early 1970’s, it was suggested that the cap structure of NNS viral mRNAs was formed by a
mechanism which was unique from eukaryotic cap formation. For VSV [6], RSV [61], and spring
viremia of carp virus [62], the two italicized phosphates of the 5′Gppp5′NpNpN triphosphate
bridge have been shown to be derived from a GDP donor, rather than GMP. However, further
studies on this mechanism have been seriously hampered due to the fact that the VSV capping
events are tightly coupled to transcription and the capping machinery does not respond to exog‐
enous transcripts. In 2007, this unique capping mechanism was revealed using a novel trans cap‐
ping assay, in which a short mRNA corresponding to the first 5-nt of VSV gene start sequence
was capped by a highly purified L protein in trans [12]. Specifically, capping of VSV mRNA was
achieved by a novel polyribonucelotidyltransferase (PRNTase) which transferred a monophos‐
phate RNA onto a GDP acceptor through a covalent L-RNA intermediate (Fig. 4C). In the first
step, a GTPase associated with the VSV L protein removes the γ-phosphate group of GTP to gen‐
erate GDP, an RNA acceptor. In the second step, the PRNTase activity of the L protein specifical‐
ly transfers a 5′-monophosphorylated (p-) RNA moiety of pppRNA with the conserved VSV
mRNA-start sequence (AACAG) to GDP to yield a GpppA capped mRNA. Interestingly, this
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unusual VSV capping enzyme caps RNA in a sequence specific manner [12]. Specifically, VSV L
protein  efficiently  capped  pppApApCpApG  (the  mRNA  gene  start  sequence),  but  not
pppApCpGpApA (the leader RNA start sequence). In addition, the VSV L protein was not able
to cap ppApApCpApG, suggesting that the L protein specifically recognizes the 5′-triphos‐
phorylated AACAG. Further mutagenesis analysis has shown that the APuCNG (Pu, purine)
sequence acts as a cis-acting element for the RNA capping reaction for the VSV L protein [12].
Figure 4. Comparison of mRNA cap formation in eukaryotic cells, WNV, and VSV. (A) Cellular mRNA cap forma‐
tion. First, pppNNNN-RNA is hydrolyzed by an RNA triphosphatase (RTPase) to yield the diphosphate ppNNNN-RNA.
Second, an RNA guanylyltransferase (GTase) transfers GMP to ppNNNN-RNA to yield GpppNNNN-RNA. Third,
GpppNNNN-RNA is methylated by G-N-7 MTase to yield 7mGpppNNNN-RNA. Fourth, 7mGpppN-RNA is further methy‐
lated by a 2’-O MTase to yield 7mGpppNmNNN-RNA. (B) WNV mRNA cap formation. First, pppNNNN-RNA is hydro‐
lyzed by viral NS3 protein (RTPase) to yield ppNNNN-RNA. Second, viral NS5 protein (GTase) transfers GMP to
ppNNNN-RNA to yield GpppNNNN-RNA. Third, GpppNNNN-RNA is methylated by N-terminus of NS5 (G-N-7 MTase) to
yield 7mGpppNNNN-RNA. Fourth, 7mGpppN-RNA is further methylated by N-terminus of NS5 (2’-O MTase) to yield
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7mGpppNmNNN-RNA. (C) VSV mRNA cap formation. First, a GTPase (CR V of L protein) removes the γ-phosphate
group of GTP to generate GDP. Second, a polyribonucelotidyltransferase (PRNTase) (CR V of L protein) transfers a
monophosphate RNA onto a GDP acceptor through a covalent L-RNA intermediate to GpppAACAG-RNA. Third, the
cap structure is methylated a 2’-O MTase (CR VI of L protein) to yield GpppAmACAG-RNA. Fourth, GpppAmACAG-RNA
is further methylated a G-N-7 MTase (CR VI of L protein) to yield 7mGpppAmACAG-RNA.
It has been a challenge to locate the active site for the novel PRNTase in the 241 kDa L protein.
The only suggestive information regarding the location of the capping enzyme in L protein has
come from the study of a novel inhibitor of the RSV polymerase which resulted in the synthesis
of short uncapped viral RNAs in vitro [63]. Viral mutants resistant to this inhibitor were select‐
ed, and the resistance mutations were mapped to CR V, suggesting that CR V of L plays a role in
mRNA cap formation. Sequence alignments of this region of L protein identified a total of 17
residues that were conserved among the NNS RNA viruses [16]. Guided by this information,
an extensive mutagenesis analysis was performed within this region which led to the discov‐
ery of a new motif GxxT[n]HR composed of four amino acid residues (G1154A, T1157A,
H1227A, and R1228A) in VSV L protein which are essential for mRNA cap formation [16]. In vi‐
tro RNA reconstitution assays have shown that these cap defective polymerases synthesized
uncapped mRNAs that terminated prematurely. The size of these abortive transcripts ranged
from 100 nt up to the full-length N mRNA, although the majority were less than 400 nt. Consis‐
tent  with their  inability  to  generate  capped RNA during in  vitro  transcription reactions,
G1154A, T1157A, H1227A, and R1228A were defective in trans capping of the 5-nt VSV gene
start sequence, demonstrating that these amino acids in CR V of L protein are required for
mRNA cap addition [16]. Importantly, GxxT[n]HR is highly conserved in the CR V of L pro‐
teins of all NNS RNA viruses, including Borna disease virus which replicates in nucleus. Fur‐
ther  biochemical  and  mass  spectrometric  analyses  found  that  H1227  in  the  conserved
GxxT[n]HR motif of the VSV L protein is covalently linked to the 5′-monophosphate end of the
RNA through a phosphoamide bond [13]. Therefore, amino acid residue H1227 is the active
site of the PRNTase activity. Mutagenesis analysis also found that R1228A and R1228K muta‐
tions significantly decreased L-pRNA complex formation activities, suggesting that mutation
in R1228 may affect the H1227-RNA intermediate formation [13]. Interestingly, this PRNTase
activity was also found in L protein of Chandipura virus (CHPV), a rhabdovirus that is closely
related to VSV [64]. Furthermore, mutations to HR motif in L protein of CHPV significantly re‐
duced the formation of the L-pRNA covalent intermediates in the PRNTase reaction. These re‐
sults  demonstrate  that  this  unconventional  capping  mechanism  is  conserved  in  the
Rhabdoviridae family. Given the fact the HR motif is highly conserved in L proteins of NNS RNA
viruses, it is likely that this novel capping mechanism is not only unique to rhadoviruses, but
also may be utilized by other NNS RNA viruses.
5. An unusual mechanism of mRNA cap methylation in VSV
5.1. Conventional mRNA cap methylation in eukaryotic cells
In eukaryotic cells, the capped mRNA (GpppN-RNA) is typically methylated by two steps
(Fig.4A) [65-68]. First, the capping guanylate is methylated by a G-N-7 methyltransferase
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(MTase) to yield 7mGpppN-RNA (cap 0). Second, the G-N-7 methylated cap structure can
then be further methylated by a ribose-2’-O (2’-O) MTase to yield 7mGpppNm-RNA (cap 1).
During mRNA cap methylation, S-adenosyl-L-methionine (SAM) serves as the methyl do‐
nor, and the by-product S-adenosyl-homocysteine (SAH) is the competitive inhibitor of the
SAM-dependent MTase. These mRNA cap methylation reactions are conserved among all
eukaryotes. In this conventional methylation reaction, G-N-7 methylation occurs prior to 2’-
O methylation and the two methylase activities are carried out by two separate enzymes,
each containing its own binding site for the methyl donor, SAM.
Many viruses encode their own mRNA cap methylaion machinery, the best-studied exam‐
ple of which is the poxvirus vaccinia virus. For vaccinia virus, the G-N-7 and 2’-O MTase
activities are encoded by two separate viral proteins, D12L and VP39 [65, 68-70]. In the case
of reovirus, G-N-7 and 2’-O MTases are catalyzed by two separate domains of the same viral
polymerase protein [55, 71]. For VSV, G-N-7 and 2’-O MTases are accomplished by a single
region (CR VI) located in the C terminus of viral polymerase protein, L (Fig.4C) [14, 17, 19].
Soon after the discovery of the dual MTase activities of VSV, the N terminus of flaviviruses
polymerase protein (NS5) was found to encode both G-N-7 and 2’-O MTases (Fig.4B)
[72-74]. In addition to this unusual dual MTase activity of CR VI, the order of mRNA cap
methylation in VSV is unconventional in which 2’-O methylation precedes and facilitates the
G-N-7 methylation [17, 18]. This is contrast to all known mRNA cap methylation reactions
including flaviviruses.
5.2. A single MTase catalytic site in CR-VI of L protein essential for both G-N-7 and 2’-O
methylation
The SAM-dependent MTase superfamily contains a series of conserved motifs (X and I to
VIII) [75]. The crystal structure of several known 2’-O MTases including E. coli heat shock-
induced methyltransferase RrmJ/FtsJ and vaccinia virus VP39 have been solved[67, 68, 70,
76]. In RrmJ, a catalytic tetrad of residues: K38, D124, K164, and E199 formed the active site
of 2’-O MTase [67, 76]. Site-directed mutagenesis of RrmJ found that a catalytic triad of resi‐
dues K38, D124, and K164 are essential for 2’-O MTase whereas E199 plays only a minor role
in the methyltransferase reaction in vitro. In vaccinia virus VP39, four amino acids, K41,
D138, K175, and E207, are essential for catalysis [68, 70]. By comparing the amino acid se‐
quence of the RrmJ and VP39 with CR VI of the L protein of NNS RNA viruses, it was sug‐
gested that this region of L protein might function as a 2′-O MTase. Sequence alignments
suggest that residues K1651, D1762, K1795, and E1833 of the VSV L protein correspond to a
catalytic KDKE tetrad (Fig.5). In fact, this KDKE motif is conserved in CR VI of L proteins of
all NNS RNA viruses with the exception of Borna disease virus. Li et al., (2005) performed
an extensive mutagenesis analysis in this predicted MTase catalytic KDKE tetrad in VSV L
protein [14]. Recombinant VSVs carrying individual substitutions to K1651, D1762, K1795,
and E1833 were recovered from an infectious cDNA clone of VSV. Analysis of the cap struc‐
ture of mRNA synthesized in vitro revealed that alterations to the predicted active site resi‐
dues abolished both G-N-7- and ribose 2′-O MTase activities. This result demonstrated that
a single KDKE tetrad in CR-VI of the VSV L protein is essential for mRNA cap G-N-7- and
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ribose 2′-O methylation [14]. Two models have been proposed to explain this result. One
possibility is that CR VI functions as both G-N-7 and 2’-O MTases. However, this conflict the
fact that all known G-N-7 and 2’-O MTases have distinct biochemistry during RNA methyl‐
ation reactions. An alternative explanation is that there is a sequential model for VSV
mRNA cap methylation in which the product of one MTase acts as the substrate for the sec‐
ond (discussed below).
Figure 5. Structure-based amino acid sequence alignments of conserved domain VI of representative NNS RNA virus L
proteins with known 2'-O methyltransferase, the E. coli RrmJ and vaccinia virus VP39. The conserved motifs (X and I to
VIII) correspond to the SAM-dependent MTase superfamily. MTase catalytic site is shown by pink color. SAM binding
site are shown by yellow color. Conserved aromatic residues are shown by blue color. Predicted alpha-helical regions
are shown by the cylinders and the ß-sheet regions by the arrows. STR, structure of RrmJ and predicted structure for
the NNS RNA viruses; EBOM, Ebola virus; VSIV, VSV Indiana type; HRSV, human respiratory syncytial virus; RRMJ, E. coli
heat shock 2'-O MTase; VP39, vaccinia virus 2'-O MTase VP39.
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5.3. A single SAM binding site in L protein essential for both G-N-7 and 2’-O methylation
The SAM-dependent MTase superfamily usually contains a G-rich motif (GxGxG) and an
acidic residue (D/E) that is involved in SAM binding [75]. Sequence alignments between
CR VI of NNS RNA virus L proteins and known MTases suggest that the SAM-binding
residues of VSV L include G1670,  G1672,  G1674,  G1675,  and D1735 (Fig.5).  Site-directed
mutagenesis has been performed to define the roles of these amino acids in VSV mRNA
methylation [17]. Each of these residues was individually substituted for alanine (A); or,
for  G4A,  all  four  G residues were replaced with A;  for  G4AD, residue D1735 was also
replaced with A. In addition,  the flanking amino acid residues D1671 and S1673 within
GDGSG motif  were  also  substituted.  Recombinant  viruses  were  recovered from each of
the L gene mutations. It was found that mutations to G1670, G1672, and S1673 specifical‐
ly diminished G-N-7,  but  not  2’-O methylation,  suggesting that  2’-O methylation occurs
prior  to  G-N-7  methylation  in  VSV  [17].  In  contrast,  mutants  D1671,  G4A,  G4AD,
G1675A,  and D1735  were  defective  in  both  2'-O  and G-N-7  methylations.  Interestingly,
mutant G1674A requires a higher concentration of SAM to achieve full methylation com‐
pared with wild type VSV and methylation is  more sensitive to  SAH inhibition.  There‐
fore,  amino acid substitutions  to  the  predicted SAM binding site  disrupted methylation
at the G-N-7 position or at both the G-N-7 and ribose 2′-O positions of the mRNA cap.
However,  none  of  these  mutants  are  specifically  defective  in  2’-O  methylation  alone.
These studies provide genetic evidence that the two methylase activities share one single
SAM binding site and, in contrast to other cap methylation reactions, methylation of the
G-N-7 position is not required for 2′-O methylation.
5.4. Mapping the potential RNA binding site that required for mRNA cap methylation
To acquire  methylation,  the  MTase  usually  directly  or  indirectly  contacts  an  RNA sub‐
strate.  This  putative  substrate  binding  site  is  poorly  understood  in  NNS  RNA  viruses.
However,  this  substrate  binding  site  has  been  identified  in  several  cellular  and  viral
mRNA 2'-O MTases [67,  68,  70,  74,  77,  78].  To achieve 2'-O methylation,  the RNA sub‐
strate interacts with the cap recognition site which requires stacking between the base of
the cap and aromatic  rings from a MTase [76,  79,  80].  Vaccinia VP39 is  one of  the best
characterized  2'-O  MTases.  In  VP39,  it  was  found that  the  recognition  of  a  methylated
base  is  achieved  by  stacking  between  two  aromatic  residues  (Y22  and  F180)  and  the
methyl  group is  in  contact  with residue Y204 (Fig.6A) [68,  70,  79].  In  addition,  the car‐
boxyl groups of residues D182 and E233 form hydrogen bonds with the NH and NH2 of
the guanosine in VP39 (Fig.6A).  Based on structure modeling and mutagenesis  analysis,
it  was shown that  residue F24 in West  Nile  virus (WNV) methylase (NS5)  [81,  82]  and
Y29 and F173 in feline coronavirus 2'-O MTase (nsp16) [80] may play an equivalent role
to  residue  Y22  in  VP39  of  vaccinia  virus.  The  cellular  cap  binding  protein-eukaryotic
translation initiation factor 4E (eIF-4E) recognizes the cap by stacking between W56 and
W102 [83].  In  all  known cases,  aromatic  residues are  involved in  cap binding and sub‐
strate recognition.
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Figure 6. The predicted structure of CR VI of VSV L protein. (A) Cap binding site of vaccinia virus 2'-O MTase,
VP39. The model was generated from the crystal structure of VP39 (PDB code: 1AV6) using PyMOL. The side chains of
amino acid residues (Y22, F180, E233 and D182) involved in binding of 7mGp cap are shown as sticks. (B) The predict‐
ed structure of CR VI of VSV L protein. The model was generated based on the previous predicted structure of VSV
MTase (amino acid residue from 1644 to 1842 in L protein) using PyMOL software. Alpha helices are shown in blue
and beta strands are shown in pink. SAM and the side chains of critical residues are shown in sticks, and the oxygen
atoms and nitrogen atoms are shown in red and blue, respectively. For SAM molecule, the carbon atoms are green.
For the three important amino acids (Y1650, F1691 and E1764) that may be involved in RNA substrate binding, their
side-chain carbon atoms are highlighted in orange. For the predicted catalytic residues (K1651, D1762, K1795 and
E1833), the carbon atoms are shown in purple.
Guided by this information, the putative RNA binding site in VSV L protein was searched
through mutagenesis analysis of selected conserved residues in region VI of VSV L protein
that were physiochemically similar to those involved in substrate recognition in VP39. Se‐
quence alignment showed that there are a number of aromatic residues that are highly con‐
served in the MTase domain of L proteins of NNS RNA viruses (Fig. 5). Aromatic residues
at positions 1650 (Y), 1691(F or Y), and 1835 (Y) are highly conserved in L proteins of NNS
RNA viruses. Aromatic residues at positions 1742 (W), 1744 (Y), 1745 (F), and 1816 (F) are
conserved in the L proteins of Rhabdoviridae and some Paramyxoviridae and Filoviridae. There‐
fore, these aromatic residues were selected as putative equivalents of Y22, F180, and Y204 in
VP39. However, there is no amino acid precisely aligned with D182 and E233 in VP39. With
the exception of two acidic amino acids in the catalytic site (K1651-D1762-K1795-E1833), po‐
sition E1764 is also conserved in all L proteins. Thus, E1764 was selected as a candidate for
mimicking the role of VP39 residues D182 and E233. In addition, two serine mutations at the
two most conserved positions at 1693 and 1827 of VSV L protein was also examined, based
on the fact that it has been shown that a serine residue was involved in RNA-protein interac‐
tion in E. coli 2'-O MTase, RRMJ [67, 77]. To determine the role of these amino acid residues
in mRNA cap methylation, a single point mutation was introduced to an infectious clone of
VSV and recombinant VSVs harboring these mutations were recovered [84]. The importance
of the maintenance of the aromatic ring at amino acids Y1650 and F1691 was revealed by the
observation that the substitution of Y1650 and F1691 with two other possible aromatic resi‐
dues in the VSV infectious clone still produced viable recombinant viruses and produced a
fully methylated mRNA cap, but alanine substitutions dramatically inhibited viral replica‐
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tion and completely blocked both G-N-7 and 2’-O methylation [84]. Based on the predicted
structural model for the VSV MTase (amino acid residues from 1644 to 1842 in the L protein)
(Fig.6B), the residues Y1650 and F1691 are located far from each other with a distance of 17.3
Å between their alpha carbon atoms. Y1650 is located in the middle of the first helix, and the
F1691 is at the very C-terminal of the second helix. Perhaps, a stacking interaction with one
aromatic residue causes a conformational and structural change in the VSV methylase,
which results in the interaction with another aromatic residue. Changing of residue E1764 to
D (maintenance of charge), Q (maintenance of size), or K (changing charge), even the very
conservative change to D, dramatically inhibited both G-N-7 and 2'-O methylation [84]. The
predicted structure of VSV MTase also shows that E1764, the residue adjacent to the catalyt‐
ic residue D1762, is exposed to the putative SAM binding site (Fig.6B). The side chain of
E1764 shows close contact to the adenyl group of SAM (3.1 Å). In addition, it was found that
Y1835A was found to require a higher SAM concentration to achieve full methylation and it
is more sensitive to MTase inhibitor [84].
To date, this work is the first attempt toward elucidation of the putative RNA substrate recogni‐
tion site in the L protein of NNS RNA viruses, which has shed light on the possible role of several
conserved aromatic amino acids, including Y1650 and F1691, in RNA binding during cap meth‐
ylation. It would provide much more direct evidence for the role of these key amino acids in me‐
diating RNA binding if the RNA binding efficiency could be measured directly. Attempts to use
a gel shift assay have failed to this end [84], as the existence of multiple RNA binding sites in L
protein with a size as large as 241-kDa posed a tremendous challenge in discerning the effect of
single point mutation. The use of a truncated CR VI of VSV L for in vitro RNA binding assays
might be a useful alternative strategy for future studies.
5.5. An unusual order for mRNA cap methylation in VSV
For conventional mRNA cap methylation, two separate MTases sequentially methylated the
cap structure, first at the G-N-7 position and subsequently at the ribose 2′-O position [65, 66].
Analysis of the cap methylation of mRNA synthesized in vitro suggests that mRNA cap methyla‐
tion in VSV is unusual, with methylation of ribose 2′-O occurring prior to G-N-7 methylation.
First, early studies showed that at low concentrations of SAM, VSV mRNA was methylated at
the 2’-O position only [85]. However, it could be chased into a doubly methylated cap structure
at high SAM concentrations in vitro. Second, when in vitro mRNA synthesis was performed in
the presence of MTase inhibitors such as SAH and sinefungin, G-N-7 methylation was inhibited
prior to 2’-O methylation [86]. Third, a host range mutant of VSV, hr8, was shown to synthesize
mRNA cap structures that lacked G-N-7 but were partially 2′-O-methylated [46, 87]. Finally,
VSV mutants carrying mutations in the SAM binding site (such as G1670A, and G1672A) are spe‐
cifically defective in G-N-7, but not 2’-O methylation [17].
This unusual order of VSV mRNA cap methylation was also biochemically demonstrated by
a trans-methylation assay in which both ribose 2′-O and G-N-7 MTases were recapitulated
by using purified recombinant L and in vitro-synthesized RNA [18]. It was found that VSV L
modifies the 2′-O position of the cap prior to the G-N-7 position and that G-N-7 methylation
is diminished by pre-2′-O methylation of the substrate RNA [18], providing compelling evi‐
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dence that 2′-O methylation precedes and facilitates G-N-7 methylation. In light that both
two MTase activities appear to reside in the same domain of L protein with the same SAM
binding site, it is conceivable that mRNA cap and/or the SAM binding site might need to be
repositioned at the end of the first methylation reaction to facilitate the second round of
methylation. How this coordination happens in vitro is still a mystery. Bearing in mind that
G-N-7 position is upstream of the ribose 2'-O position in the mRNA strand, reorientation is
thus less likely to have resulted from forward movement of capped RNA through CR VI
during transcription, but rather it might entail a fine spatial rearrangement. Collectively,
these experiments have shown that the order of VSV mRNA cap methylation is distinct
from all other known mRNA cap methylation mechanisms.
5.6. VSV methylases require cis-element in RNA
During mRNA synthesis, the VSV polymerase initiates synthesis at the first gene-start (GS)
sequence (3′ UUGUCNNUAC 5′), and the nascent mRNA chain is capped and methylated,
and recognizes a specific gene-end (GE) sequence (3′-AUACUUUUUUU-5′), the polymerase
polyadenylates and terminates. It has been well demonstrated that the GS sequence contains
a key cis-acting regulatory element for the initiation of mRNA synthesis [31, 32]. Specifically,
the first three positions of the GS sequence have been found to be critical for mRNA synthe‐
sis. Recently, both trans capping assays with 5-nt oligo RNA substrates and detergent-acti‐
vated virus transcription reactions pointed out the importance of positions 1, 2, 3, and 5 in
mRNA cap addition, although position 5 substitutions were more tolerated [12, 31, 32]. Us‐
ing a trans methylation assay, it was found that similar signals were required for mRNA cap
methylation [18]. As expected, VSV L protein efficiently methylated a 110 nt of RNA with an
authentic gene start sequence at position 2’-O. However, when the gene start sequence of
this 110 nt was replaced with non-viral sequence (5′ GpppGGACGAAGAC-RNA), the effi‐
ciency of 2’-O methylation was reduced approximately 9 times. Similarly, VSV L protein ef‐
ficiently methylated a pre-2′-O-methylated VSV mRNA at position G-N-7. In contrast, the
efficiency of G-N-7 methylation decreased nearly 7 times when incubated with a substrate
with non-VSV mRNA start RNA. Therefore, the gene start sequence of VSV mRNA contains
a signal for initiation of mRNA synthesis, mRNA cap addition, and cap methylation.
5.7. The length of mRNA in cap methylation
In the trans mRNA capping assay, the VSV L protein efficiently caps the 5-nt gene start se‐
quence [12, 16], demonstrating that a 5-nt RNA substrate is sufficient for mRNA cap addi‐
tion. In order to determine the minimum length of RNA required for mRNA cap
methylation, 5-,10-, 51-, and 110-nt RNAs were used as substrates for a trans methylation as‐
say in vitro [18]. Interestingly, the 10-, 51-, and 110-nt RNAs were able to serve as substrates
for both G-N-7 and ribose 2'-O methylations, whereas the 5-nt RNA was not methylated by
the VSV L protein at either the G-N-7 or the ribose 2'-O position [18]. Therefore, in contrast
to trans capping, a 5-nt substrate is not sufficient for trans methylation and likely the con‐
served positions 8, 9, and 10 in VSV gene start sequence are required for mRNA cap methyl‐
ation. Clearly, the length of RNA required for methylation is longer than that required for
capping by the VSV L protein.
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5.8. Model for mRNA cap methylation
The process of VSV L protein-mediated cap methylation can be best summarized with the
following model (Fig.7). Initially in response to a specific cis-acting element in the VSV gene
start sequence, CR VI of L protein methylates the cap structure first at the 2'-O position to
produce GpppAmACAG-RNA. The by-product of this reaction, SAH, is released from this
reaction. Following 2’-O methylation, a second molecule of SAM binds to CR VI of L protein
that may facilitate a subsequent methylation of the RNA at the G-N-7 position. Methylation
at the 2'-O position favors G-N-7 methylation in the cap structure through a currently un‐
known mechanism. G-N-7 methlyation may be facilitated by the contact with the RNA mol‐
ecule remains bound to the L protein at the end of the initial methylation at the 2'-O
position. Another possibility is that CR VI of L protein exists in two different conformations.
An initial conformation may favor binding of GpppRNA and SAM. Methylation of RNA at
the 2'-O position perhaps induces a conformational change that facilitates the repositioning
of the RNA for subsequent G-N-7 methylation, and/or favors the release of SAH as well as
the binding of a subsequent molecule of SAM.
5.9. Comparison of mRNA cap methylation in VSV and WNV
To date, the rhabdovirus, VSV, and the flavivirus, WNV, are the two best characterized vi‐
ruses that utilize a single region in the polymerase protein for both G-N-7 and 2'-O methyla‐
tions. However, the mechanism of VSV mRNA methylation is distinct from that of the WNV
system (Fig.4B and C). In VSV, 2'-O methylation precedes and facilitates subsequent G-N-7
methylation [17, 18]. However, WNV MTases modify the cap structure, first at the G-N-7
position and subsequently at the ribose 2'-O position [72, 73, 78]. In VSV, the G-N-7 and 2'-O
MTases require similar conditions for methylation with an optimal pH at 7.0 [18]. In con‐
trast, the G-N-7 and 2'-O MTases of WNV require an optimal pH at 6.5 and 10, respectively
[72]. Both VSV and WNV MTases modify the RNA in a sequence-specific manner, but re‐
quire different elements in the RNA substrate. VSV G-N-7 and 2'-O MTases require specific
gene start sequences with a minimum mRNA length of 10 nucleotides [18]. In the WNV
model, N-7 cap methylation requires the presence of specific nucleotides at the second and
third positions and a 5' stem-loop structure within the 74-nucleotide viral RNA; in contrast,
2'-O ribose methylation requires specific nucleotides at the first and second positions, with a
minimum 5' viral RNA of 20 nucleotides in length [81]. In addition, there is striking differ‐
ence in the cap recognition site between the VSV and WNV MTases. For the WNV MTase,
the cap recognition site is essential for 2'-O, but not G-N-7 methylation [73, 82]. Consistent
with this finding, it was found that GTP and cap analogs specifically inhibited 2'-O, but not
G-N-7 methylation [73, 82]. However, mutations to the putative RNA binding site in VSV L
protein affected both G-N-7 and 2’-O methylations. GTP and cap analogs did not affect VSV
mRNA cap methylation in vitro. Overall, the mechanism of VSV mRNA cap methylation is
significantly different from that of WNV. Most recently, it was found that capping of flavivi‐
rus RNA is catalyzed by conventional RNA guanylyltransferase via a covalent GMP-en‐
zyme intermediate [88]. However, VSV capping is catalyzed by a novel PRNTase [12, 13, 16,
89]. These studies suggest that VSV and perhaps other NNS RNA viruses have evolved a
unique mechanism to add the cap to their mRNA and to methylate the cap structure.
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Figure 7. Proposed model for mRNA cap methylation in VSV and eukaryotic cells. (A) VSV MTase model. VSV
mRNA cap structure is first methylated by CR VI of L protein at the 2'-O position to produce GpppAmACAG-RNA. The
by-product, SAH, is released before the binding of a second molecule of SAM. G-N-7 methlyation may be facilitated by
the contact with the RNA molecule remains bound to the polymerase at the end of the initial methylation at the 2'-O
position. Or, methylation of RNA at the 2'-O position may induce a conformational change that facilitates the reposi‐
tioning of the RNA for subsequent G-N-7 methylation. (B) Cellular MTase model. GpppNNNN-RNA is first methylated
by a G-N-7 MTase to yield 7mGpppNNNN-RNA. Following G-N-7 methylation, 7mGpppNNNN-RNA dissociates with G-
N-7 MTase, and re-associates with a separate 2’-O MTase to yield 7mGpppNmNNN-RNA. In this model, the two methyl‐
ase activities are carried out by two separate enzymes, each containing its own SAM binding site.
5.10. mRNA cap methylation in other NNS RNA viruses
Limited accomplishments have been made in understanding the mechanism of mRNA cap
methylation in other NNS RNA viruses, due to the lack of a robust in vitro mRNA synthesis for
most of NNS RNA viruses, and the technical challenge of expression and purification of a func‐
tional polymerase protein or fragment. In early 1970, Colonno and Stone showed that the NDV
mRNA cap structure was methylated only at G-N-7 [90]. This is distinct from the cap structures
of other NNS RNA viruses which typically contain two methyl groups, at positions G-N-7 and
ribose 2'-O. However, detailed characterization of the NDV methylase activities and the mech‐
anism involved in this unique methylation is not understood. The mechanism underlying this
difference and the biological significance of the lack of 2’-O MTase is not known. Sequence
analysis has revealed that the proposed SAM binding region for the Filoviridae, Rubulavirus,
and Avulavirus genera of the Paramyxoviridae contains a conserved AxGxG sequence rather
than GxGxG within motif I of the SAM-dependent MTase superfamily (Fig.8). It will be inter‐
esting to determine if there is a link between this differential SAM binding sites and the lack of
2'-O methylation in NDV. Recently, it was shown that a fragment of Sendai virus L protein that
includes CR VI was able to methylate short Sendai virus-specific RNA sequences in trans at the
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G-N-7 position [43]. However, the "trans-methylation" assay used in their study does not allow
detection of 2’-O methylation although it is known that Sendai virus encodes two MTases.
More recently, recombinant Sendai virus carrying mutations in catalytic KDKE tetrad and
SAM binding site were recovered from infectious clones [91, 92]. It was found that these muta‐
tions affected mRNA cap methylation. However, whether they are specifically defective in G-
N-7 and/or 2’-O methylation is not known because of the assay did not have the ability to
distinguish the two methyl groups. In addition, the order of methylation may be different
among NNS RNA viruses. In contrast to VSV, methylation of RSV mRNA at low SAM concen‐
trations was found at only the G-N-7 position; however, it was found to be doubly methylated
at high SAM concentrations [63]. This study provided evidence that the order of mRNA cap
methylation in RSV may be different with VSV. Clearly, more studies are needed to under‐
stand the mRNA cap methylation in other NNS RNA viruses.
Figure 8. SAM binding motifs in NNS RNA virus MTases. The proposed SAM binding region for the Filoviridae, Ru‐
bulavirus, and Avulavirus genera of the Paramyxoviridae contains a conserved AxGxG sequence rather than GxGxG.
NNS RNA viruses include VSVI, VSV Indiana; VSVN, VSV New Jersey; BEFV, bovine emphemeral fever virus; RABV, rabies
virus; Marb, Marburg virus; MeV: measles; HV, Hendra virus; NPV, Nipah virus; AMPV, avian metapneuomovirus;
HMPV, human metapneuomovirus; APMV6, avian paramyxovirus 6; MuV, mumps virus; HPIV2, human parainfluenza
virus 2; SV5, simian virus 5; SV41, simian virus 41;
SS(+) RNA: single strand positive RNA viruses include DNV, dengue virus; WNV, West
Nile virus; YFV, yellow fever virus.
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6. The effects of 5’ mRNA cap addition and cap methylation on 3’ mRNA
polyadenylation
VSV mRNA is  capped and methylated at  the 5′  end and polyadenylated at  the 3′  end.
Cap addition, cap methylation, and polyadenylation are carried out by three different re‐
gions (CR V,  CR VI,  and CR III)  in  L protein.  During VSV mRNA synthesis,  modifica‐
tions  of  the  5′  and  3′  ends  of  the  mRNAs are  tightly  coupled  to  transcription  [21-23].
Although the detailed mechanism by which the polymerase coordinates  these modifica‐
tion events is poorly understand, available evidence suggests there is a link between au‐
thentic  5′-end  formation  and  3′-end  formation  during  VSV  mRNA  synthesis.  Early
studies demonstrated that the length of poly (A) tails on VSV mRNAs is affected by the
presence  of  SAH,  the  by-product  and  competitive  inhibitor  of  SAM-mediated  methyl‐
transferases [93-95]. The fact that the polymerase can synthesize full-length mRNAs in vi‐
tro  in the absence of  SAM or in the presence of  SAH, suggests that  transcription is  not
dependent  on  cap  methylation.  When  in  vitro  transcription  reactions  are  performed  in
the presence of SAM, the RdRp synthesizes mRNA with poly (A) tail of 100 to 200 nt in
length,  similar  to  those  synthesized  in  VSV-infected  cells.  However,  when  VSV mRNA
cap methylation  was  inhibited  during  in  vitro  transcription  reactions  by  supplementing
with 1 mM SAH, the synthesized mRNA was heterogeneous in length due to having ex‐
tremely long poly (A) tails,  from 700 to 2,400 nucleotides (nt)  in length [93,  96].  Recent
work demonstrated that SAH-induced hyperpolyadenylation also occurs in cells infected
by wild-type VSV in the presence of adenosine dialdehyde (AdOX), a compound that in‐
hibits the activity of SAH hydrolase [97]. These results indicated that chemical inhibition
of  VSV  mRNA  cap  methylation  by  SAH  resulted  in  hyperpolyadenylation  of  viral
mRNA.  Interestingly,  this  hyperpolyadenylation  of  VSV  mRNAs  has  been  observed  in
ts(G)16, a VSV mutant identified in 1970 based on its ability to grow at 31°C but not at
39°C [93, 98, 99]. In the absence of SAH, the mRNAs synthesized by VSV mutant ts(G)16
were  hyperpolyadenylated  at  the  3′  end.  Genomic  sequence  analysis  found  that  the  L
protein  of  ts(G)16  contains  two  amino  acid  changes,  C1291Y  and  F1488S,  compared  to
wild type. Combined with the analysis of revertants of ts(G)16, it was found that F1488S,
located in the variable region of L between CR V and CR VI,  is  responsible for the hy‐
perpolyadenylating phenotype.
The characterization of a panel of MTase-defective VSVs may serve as a tool to understand
the mechanism by which SAH or the failure to methylate the cap structure results in hyper‐
polyadenylation. It was found that rVSV-K1651A, a mutation in MTase active site and com‐
pletely defective in G-N-7 and 2’-O methylation, synthesized excessively long poly(A) tails,
similar to those produced by wild-type L in the presence of SAH [15]. Similarly, the substi‐
tution D1762E at the MTase active site, which inhibits both G-N-7 and 2’-O methylation,
produces large polyadenylate in the presence or absence of SAH [97]. This data confirms the
earlier work demonstrating that the inhibition of cap methylation results in large polyade‐
nylate. In contrast, several other substitutions that inhibit cap methylation, including
D1762G, D1762N, G1672P, and G1675P, did not produce hyperpolyadenylated mRNA [97].
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Perhaps, K 1651A and D1762E substitutions might favor the binding of SAH at the SAM
binding site in CR VI, resulting in hyperpolyadenylation without the need for supplemental
SAH. Clearly, further studies are needed to understand the relationship between 5’ mRNA
cap methyaltion and 3’ polyadenylation.
However, it appears clear that 5’ cap addition is required for 3’ polyadenylation, as evi‐
denced by the polymerase mutants (G1154, T1157, H1227, and R1228) within CR V of L that
inhibited cap addition also inhibit polyadenylation [15]. These cap-defective polymerases
synthesized truncated transcripts that predominantly terminated within the first 500 nt of
the N gene and contained short A-rich sequences at their 3′ termini. To examine how the
cap-defective polymerases respond to an authentic VSV termination and re-initiation signal
present at each gene junction, a 382 nt gene was inserted at the leader-N gene junction in the
VSV genome. Using this N-RNA as the template, the cap-defective polymerases were able to
synthesize full-length 382-nt transcripts that were not capped at 5’end. Interestingly, these
uncapped transcripts lacked an authentic polyadenylate tail and instead contained 0 to 24 A
residues [15]. In addition, the cap-defective polymerases were also unable to efficiently copy
the downstream genes [15]. This finding strongly supports that 5′ mRNA cap addition and
3′ polyadenylation are mechanistically and functionally linked.
7. Impact of mRNA cap methylation on viral replication and gene
expression
In eukaryotic cells, it is well established that G-N-7 methylation of the mRNA cap structure
is essential for mRNA stability and efficient translation [11, 48, 66]. Specifically, G-N-7 meth‐
ylation of the mRNA cap structure is required for recognition of the cap by the rate limiting
factor for translation initiation, eIF-4E [100, 101]. The mRNA cap structures of NNS RNA vi‐
ruses are typically G-N-7 and 2’-O methylated. Although the precise mechanism by which
VSV mRNAs are translated is unclear, they are broadly thought to utilize a variation of the
canonical cap-dependent translational pathway [102-104]. In VSV-infected cells, host mRNA
translation is rapidly inhibited through the suppression of the intracellular pools of eIF-4E
by a manipulation of the phosphorylation status of the 4E binding protein (4E-BP1) [104].
Nevertheless, in vitro experiments have shown that G-N-7 cap methylation facilitates trans‐
lation of VSV proteins. MTase-defective VSV would provide a tool to study the role of
mRNA cap methylation in viral protein synthesis. Ultimately, it will affect viral genome rep‐
lication and gene expression since viral replication requires ongoing protein synthesis.
Based on the status of mRNA methylation, MTase-defective VSVs can be classified into
three groups [14, 17, 84]. Viruses in the first group are completely defective in both G-N-7
and 2’-O methylation, including mutations in MTase active site (rVSV-K1651A, D1762A,
K1795A, E1833Q, and E1833A), SAM binding site (rVSV-D1671V, G1675A, G4A, and
G4AD), and putative RNA binding site (rVSV-Y1650A, F1691A, and E1764A). Viruses in the
second group are specifically defective in G-N-7, but not 2’-O MTase, including mutants in
SAM binding site (rVSV-G1670A, G1672A, and S1673A). Viruses in third group that require
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elevated SAM concentrations to permit full methylation including a mutant in SAM binding
site (rVSV-G1674A) and putative RNA binding site (rVSV-Y1835A). With the exception of
rVSV-G1674A and Y1835A, all MTase-defective VSVs were attenuated in cell culture as
judged by diminished viral plaque size, reduced infectious viral progeny release (in single-
step growth curves), and decreased levels of viral genomic RNA, mRNA, and protein syn‐
thesis. It appears that the degree of attenuation is consistent with the defects of the
methylation. For example, viruses defective in both G-N-7 and 2’-O methylation had 2-5 log
reductions in growth whereas viruses only defective in G-N-7 had 1-2 log declines in repli‐
cation [14]. Recombinant rVSV-G1674A and Y1835A replicated as efficiently as wild type
rVSV [14]. A remarkable finding is that some of the mutants in the SAM binding site (rVSV-
G1675A, G4A, and G4AD) affected transcription and replication differently [17]. For these
mutants, replication was enhanced 2.5- to 4-fold, and transcription decreased up to 8-fold
compared with rVSV. One feature of the gene expression strategy of NNS RNA viruses is
that the polymerase complex controls two distinct RNA synthetic events: genomic RNA rep‐
lication and mRNA transcription [20, 105, 106]. It is possible that SAM binding influences
the switch of polymerase between replicase and transcriptase. Perhaps, L protein with SAM
binding favors to function as transcriptase, whereas L protein that lacks SAM binding favors
replicase function.
8. Impact of mRNA cap methylation on viral pathogenesis in vitro
Although it is well studied that MTase-defective viruses were attenuated in cell culture, the
impact of mRNA cap methylation on viral pathogenesis in vitro is poorly understood. Re‐
cently, Ma et al., (2012) examined the pathogenicity of MTase-defective VSVs in mice [107].
VSV infects a wide range of wild and domestic animals such as cattle, horses, deer, and pigs,
characterized by vesicular lesions in the mouth, tongue, lips, gums, teats, and feet. Although
the mouse is not the natural host of VSV, it represents an excellent small animal model to
understand VSV pathogenesis because VSV causes systemic infection and fatal encephalitis
[108-110]. After intranasal inoculation, VSV infects olfactory neurons in the nasal mucosa
and subsequently enters the central nervous system (CNS) through the olfactory nerves. The
virus is then disseminated to other areas in the brain through retrograde and possibly ante‐
rograde trans-neuronal transport, ultimately causing an acute brain infection. It was found
that VSV mutants, rVSV-K1651A, D1762A, and E1833Q, which have mutations in the MTase
catalytic site and are defective in both G-N-7 and 2’O methylation, were highly attenuated in
mice [107]. Mice inoculated with these recombinant viruses did not show any clinical signs
of VSV infection such as weight loss, ruffled fur, hyperexcitability, tremors, circling, and pa‐
ralysis. Furthermore, these mutant viruses were not able to enter the brain, had dramatic de‐
fects in replication in lungs, and did not cause significant histopathological changes in lungs
and brain. Recombinant rVSV-G1670A and G1672A, which have mutations in the SAM
binding site and are defective in G-N-7 but not 2’-O methylation, retained low virulence in
mice [107]. Mice inoculated these two recombinants exhibited weight loss of approximately
2-3 g during days 3-7 post-inoculation and showed mild illnesses such as ruffled coat for 2-3
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days but recovered quickly. But, none of mice in rVSV-G1670A and G1672A had neurologi‐
cal symptoms. These two recombinants had moderate defects in replication in lungs and
brain, and caused moderate histopathological changes in lungs. Interestingly, recombinant
rVSV-G4A, which carries four mutations (G1670A, G1672A, G1674A, and G1675A) in SAM
binding site and is completely defective in both G-N-7 and 2’-O methylation, exhibited an
interesting pathotype [107]. Similar to VSV mutants at the MTase catalytic site, rVSV-G4A
had dramatically impaired viral replication in the lungs and brain of the mice. However, the
rVSV-G4A group exhibited body weight losses that were comparable to G1670A and
G1672A, and clinical signs that were more severe than G1670A and G1672A. These results
suggest rVSV-G4A retained low to moderate virulence despite the fact that it was attenuat‐
ed for replication and or spread in vitro. As predicted, recombinant rVSV-G1674A, which
contains a point mutation in the SAM binding site and requires elevated SAM concentra‐
tions to permit full methylation, was highly virulent to mice. These results suggest that (i)
the relationship between mRNA cap methylation and viral pathogenesis is not clear cut in
VSV infections; and (ii) inactivation of the predicted catalytic residues attenuates the virus to
a greater extent in vitro, than does inactivation of the predicted SAM binding site.
9. 2’-O methylation and innate immunity
While it is firmly established that G-N-7 methylation is essential for mRNA stability as well
as efficient translation, the role(s) of ribose 2’-O methylation have proven more elusive. Re‐
cent studies on West Nile virus (WNV) suggest that the 2′-O methylation of the 5′ cap of
viral RNA functions to evade innate host antiviral responses through escape of the suppres‐
sion of interferon-stimulated genes, tetratricopeptide repeats (IFIT)[111]. Specifically, mu‐
tant WNV (E218A) defective in 2′-O MTase activity was attenuated in wild-type C57BL/6
mice, but remained pathogenic in knockout mice that lacked the type I interferon (IFN) sig‐
naling pathway. In addition, a vaccinia virus mutant (J3-K175R) and mouse hepatitis virus
(MHV) mutant D130A, both of which lacked 2′-O MTase activity, exhibited enhanced sensi‐
tivities to the antiviral actions of IFN mediated by IFIT proteins. Interestingly, it was also
reported that 2’-O methylation of mouse and human coronavirus RNA facilitates evasion
from detection by the cytoplasmic RNA sensor Mda5 [112]. Taken together, these studies
suggest that 2’-O methylation of viral RNA provides a molecular signature for the discrimi‐
nation of self and non-self mRNA. It is known that mRNAs of most NNS RNA viruses con‐
tain G-N-7 and 2’-O methylation. However, whether 2’-O methylation plays a similar role in
all NNS RNA viruses is not known.
VSV is an excellent model to aid in the understanding the role of viral mRNA cap methyla‐
tion in innate immunity. The mechanism of VSV mRNA cap methylation is unique in that
2’-O methylation precedes and facilitates the G-N-7 methylation [17, 18]. It is unknown why
the order of VSV mRNA methylation is reversed compared to all known mRNA cap methyl‐
ation reactions. One possibility is that the methylation of 2’-O allows VSV to successfully
mimic cellular mRNA to avoid the detection by host innate immunity, which in turn pro‐
motes efficient viral replication in hosts. In fact, VSV is one of only a few viruses that repli‐
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cates efficiently in a wide range of cell lines including mammalian cells, insect cells, and
worms [113]. Unlike WNV, VSV that is specifically defective in G-N-7 methylation can also
be successfully recovered [17]. VSV mutants defective in G-N-7 methylation or both G-N-7
and 2’-O methylations can serve as prototypes or controls to elucidate the role of methyla‐
tion in innate immunity. In addition, the VSV mutant (rVSV-G4A) that was attenuated in
cell culture retained low to moderate virulence, suggesting the possible role of methylation
in averting the innate immune response [107]. Notably, mRNAs of NDV, an avian paramyx‐
ovirus, are not 2’-O methylated [90]. A direct comparison to determine whether 2’-O meth‐
ylation of VSV has a similar biological function compared to WNV and MHV should prove
very compelling.
10. MTase-defective viruses as live vaccine candidates
Recombinant viruses defective in MTase can be recovered from cloned full-length viral
cDNA by a reverse genetics system. Viruses lacking MTase would likely be attenuated with‐
out affecting immunogenicity, since the MTase is located in L protein, which is not a neu‐
tralizing antibody target. Our group and others have identified a panel of MTase-defective
VSV mutants which are attenuated in cell culture as well as in animal models [14, 17, 84,
107]. In addition, MTase-defective Sendai viruses also showed significant defects in viral
growth in cell culture [91, 92]. By combining multiple substitutions within the methylation
region, it should be possible to generate an attenuated virus that is genetically stable, as re‐
version to wild type at any single amino acid should not provide a fitness gain. Thus, ablat‐
ing viral mRNA cap methylation would provide a new avenue to rationally attenuate these
viruses for the development of live attenuated vaccines and exploit their use as viral vectors
for vaccines, oncolytic therapy, and gene delivery. Recently, Ma et al., (2012) showed that
MTase-defective VSVs were able to induce high levels of VSV-specific antibodies in mice
and thus provided full protection against a virulent challenge with the VSV Indiana sero‐
type [107]. Recombinants rVSV-K1651A, D1762A, and E1833Q which were defective in both
G-N-7 and 2’-O methylation, are attractive vaccine candidates since they are not only highly
attenuated but also retain high immunogenicity. Although recombinants rVSV-G1670A and
G1672A retained low virulence to mice, their pathogenicity was significantly reduced com‐
pared to rVSV. The safety of using these two viruses as live vaccine candidates necessitates
further investigation.
Our studies on MTase-defective VSVs also shed light on developing live vaccine candidates
for other NNS RNA viruses, particularly paramyxoviruses. Within paramyxoviruses,
RSV, hMPV, and PIV3 account for the majority of  respiratory diseases infants,  children,
and the elderly [1-3]. However, there is no vaccine available for these important viruses.
Recent research found that live attenuated vaccines are the most promising vaccine can‐
didates for paramyxoviruses [1-3]. However, it has been technically challenging to isolate
a virus with low virulence while  retaining high immunogenicity.  Introducing mutations
in the MTase may provide a novel approach to generate live attenuated viruses for these
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viruses.  It  was  reported  that  recombinant  Sendai  virus  carrying  point  mutations  in  the
MTase catalytic  site  (rSeV-K1782A)  and the  SAM binding site  (rSeV-E1805A)  were  atte‐
nuated in cell culture [91]. It will be of interesting to determine whether these Sendai re‐
combinants are attenuated in vitro.
11. mRNA cap methylation as a target for anti-viral drug discovery
It appears that the entire mRNA capping and methylation machinery in NNS RNA viruses
is different from that of their hosts. This difference, coupled with the fact that replication of
NNS RNA viruses occurs in the cytoplasm, suggests that mRNA cap formation is an excel‐
lent target for anti-viral drug discovery. Inhibition of the viral mRNA cap formation would
likely inhibit downstream events such as replication, gene expression, viral spread, and ulti‐
mately viral infection. Since the mRNA of all NNS RNA viruses contains a methylated cap
structure, classes of broadly active anti-viral agents may be developed by targeting the viral
cap formation. For human RSV, several compounds were shown to inhibit polymerase activ‐
ity which resulted in the synthesis of short uncapped transcripts [63]. RSV mutants resistant
to these inhibitors were selected and sequenced. It was found that these resistant mutants
contained substitutions in CR V of L, specifically at E1269D, I1381S, and L1421F, suggesting
that the mechanism of the action of these compounds is the inhibition of viral mRNA cap
addition. Interestingly, these compounds showed strong antiviral activity against RSV infec‐
tion in cell culture as well as in a mouse model, demonstrating that mRNA cap addition is
an attractive antiviral target. It is known that SAH can inhibit viral mRNA cap methylation.
Therefore, many adenosine analogues such as 3-deazaeplanocin-A are potent antiviral
agents which can significantly inhibit VSV replication in cell culture [114, 115]. The mecha‐
nism of the action of these adenosine analogues is through the interference with the host en‐
zyme SAH hydrolase that catalyzes the hydrolysis of SAH to adenosine and L-
homocysteine. This reaction is reversible, and the products of this reaction are inhibitory to
SAH hydrolase. Obviously, compounds that directly inhibit viral mRNA cap methylation
are potent antiviral drugs. For example, sinefungin (SIN), a natural S-adenosyl-l-methionine
analog produced by Streptomyces griseolus, is an inhibitor of methyltransferases. SIN is struc‐
turally related to SAM, with the exception that the methyl group that is donated from SAM
is replaced by an amino group in SIN. Crystal structures of several MTases have been solved
in complex with SIN, which binds to a region that overlaps the SAM binding site [116]. It
was found that SIN inhibited VSV G-N-7 and 2’-O methylation with a 50% inhibitory con‐
centration (IC50) of 2.5 μM and 40 μM, respectively [86]. In cell culture, SIN efficiently inhib‐
ited VSV replication, gene expression, and diminished the size of viral plaques without
having significant effect on cell viability. SIN was also shown to inhibit the MTases of other
NNS RNA viruses such as NDV [90]. These examples demonstrate that mRNA capping and
methylation is an excellent antiviral target for NNS RNA viruses. An important future direc‐
tion is to develop high-throughput screening (HTS) to systemically screen compounds that
can inhibit mRNA capping and/or methylation of VSV and other NNS RNA viruses. These
inhibitors may be broadly active anti-viral agents against NNS RNA viruses.
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12. Concluding remarks
In recent years, significant progress has been made in understanding the unusual mechanism of
mRNA cap addition and methylation employed by VSV. First, VSV mRNA addition utilizes a
novel PRNTase that transfers RNA to the GDP acceptor. Second, VSV mRNA cap methylation is
catalyzed by a dual MTase that sequentially methylates the position 2’-O followed by G-N-7.
Third, PRNTase and dual MTase have been mapped to single amino acid level in CR V and CR VI
in the L protein, respectively. Finally, 5’ mRNA cap addition and methylation and 3’ polyadeny‐
lation are mechanistically and functionally linked. Apparently, the entire mRNA cap formation
in VSV evolves a mechanism distinct to hosts. Thus, mRNA cap modification is an ideal target
for vaccine and antiviral drug development. However, there are many questions need to be ad‐
dressed. It is not known how polymerase coordinates nucleotide polymerization, mRNA cap
addition, cap methylation, and polyadenylation. Although the general mechanism of mRNA
modifications is defined, the detailed step in each reaction is still poorly understood. The
GTPase required for mRNA capping has not been mapped in L protein. Besides the HR motif, it
is not known which step of mRNA capping was affected by other mutations (such as T1157A and
G1154A) in CR V of L protein. During mRNA cap methylation the exact mechanism by which the
dual MTase methylates the 2’-O and G-N-7 is not known. The crystal structure is not known for L
protein or any portion of L protein. The concept of using mRNA cap formation as antiviral target
has been experimentally demonstrated, however, high-throughput screening methods toward
drug discovery have not been developed. Furthermore, there is urgent need to understand the
mRNA cap modification in other NNS RNA virus although it is speculated that they may also be
achieved in a similar mechanism.
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